EVEREST-1 Trial Seeks to Bring HLA-A*02-directed CAR T to Patients With Solid Tumors


The upcoming phase 1/2 EVEREST-1 trial, where the novel CAR T-cell therapy A2B530 will be evaluated in patients with solid tumors, aims to push progress for one-and-done engineered therapies in this space.

Diane M. Simeone, MD

Diane M. Simeone, MD

The upcoming phase 1/2 EVEREST-1 trial (NCT05736731), where the novel chimeric antigen receptor (CAR) T-cell therapy A2B530 will be evaluated in patients with solid tumors, aims to push progress for one-and-done engineered therapies in this space.1

“With this trial, and some others that are coming, we're in a unique position to evaluate for the first time pretty compelling approaches in testing CAR T therapy in solid tumors,” Diane M. Simeone, MD, the director of the Pancreatic Cancer Center and the associate director of translational research at the Perlmutter Cancer Center in New York, New York, said. “I'm very excited for the opportunity to offer this therapy for our patients. [I’m also] looking forward to seeing how this approach can be best deployed and for A2B530 to broaden the portfolio of patients that will be eligible for this treatment by increasing the activator portfolio along with the HLA subtypes that are eligible for the trial.”

A2B530 targets carcinoembryonic antigen (CEA), an antigen expressed in many solid tumor types, including nearly all pancreatic and lung cancers. However, CEA is also present in some types of healthy cells such as gut epithelial cells, opening the door to the potential of on-target, off-tumor toxicity.2

Therefore, the developers of A2B530 developed a novel logic-gated T-cell platform, Tmod, to help the agent differentiate between cancer cells and healthy cells—a long-running issue in effectively applying CAR T-cell therapies in solid tumors. The CEA-directed Tmod construct A2B530 utilizes the LIR-1-based inhibitory receptor that targets HLA-A*02; the inhibitory receptor, or blocker, is able to distinguish between healthy and cancer cells by recognizing loss of heterozygosity of HLA-A*02 that is present on tumor cells.2

In an interview with OncLive®, Simeone discusses the details of the EVEREST-1 trial, what makes the methods employed in the trial particularly unique, and some of the forward-facing questions that will need to be addressed for A2B530 to truly have an impact for patients with solid tumors.

What are some of the barriers to providing effective CAR T-cell therapies for patients with solid tumors?

There have been unique challenges in solid tumors, [including] understanding the tumor microenvironment. For the tumor that I study, pancreatic cancer, that's been a particular challenge due to difficulty in tissue acquisition. However, with increasing analysis of human tumors, in particular with the burgeoning field of single-cell sequencing, we're getting a much more detailed look into the microenvironment of solid tumors and that is going to help us drive new technologies in immunotherapy.

With CAR T, there are advances in the technologic aspects of T-cell preparation, the targeting strategies, [and] the strategies to mitigate off target effects. The combination of these things coming together is hopefully poising us to move CAR T-cell therapy into effectiveness for solid tumors.

What preclinical work led to the initiation of the EVEREST-1 trial?

The concern for patients is if they undergo a tumor resection [and] have recurrence, what therapeutic options [are] available to them? As we first built out BASECAMP-1 [NCT04981119], we studied patients who underwent surgical resection who might be at high risk for recurrence and that included patients with pancreatic cancer, high-risk colon cancer, and lung cancer. With those analyses, we looked at HLA status of the patient and HLA status in the tumor—that allowed us to assemble a group of patients that, if they were to develop recurrence, would have a very viable and attractive therapeutic option.

Now that EVEREST-1 is opening at several sites around the country we can broaden access to patients across a range of tumors, growing to include ovarian, head, and neck, that have the correct HLA subtype, HLA-A*02—which is the most common HLA subtype in the United States. This represents a remarkable option for therapy. Of course, an important second part of qualifying for the trial is to have loss of heterozygosity of the HLA second allele in the tumor and that allows the CAR T to be very effective in treating the tumors with a high level of selectivity.

How was the trial schema of EVEREST-1 crafted with the BASECAMP-1 trial in mind?

The design was crafted to reflect 2 parts. The foundation is BASECAMP-1, which [aims] to identify patients around the country who qualify for entry in the study and then Everest is [assessing] the ability to deliver CAR T-cell therapy to selected patients.

We wanted to be quite broad in our approach to identify patients around the country who were eligible with BASECAMP-1 because there are some defining criteria that may not apply to all patients. There is a gradual plan to broaden the HLA subtypes that will be available for this type of therapy. For now, it's for HLA-A*02, that's going to be about 30% of the US population and from there there's going to be a subset of patients that have loss of the second HLA allele in their tumor. So, there is a funneling effect of who may be eligible.

[However], this is a great start and certainly, as the approach broadens, there'll be different activators or antigens expressed on the cell surface that [will] broaden the number of patients available. Importantly, [there will be more] approaches to mitigate the off-target effects so that you can deliver a high payload while mitigating some of the problematic [adverse] effects [AEs] that have happened with CAR T therapies for patients with solid tumors in the past.

What differentiates A2B530 from other CAR T-cell agents that have previously been tested in solid tumors?

The approach is really focused on safety and there's a number of different elements that are built in the constructs that are unique to A2B530. They spent a lot of time modeling out how to optimize the CAR T generation for effectiveness and validating those results in in vitro and in vivo models.

Importantly, both a blocker and activator are built in the same construct, such that the T cells will only target cells that have loss of HLA—that's a critical component. We have witnessed very heroic attempts to try to use CAR T in solid tumors, but we have seen that there can be some significant AEs. This approach has the ability to deliver a high payload but mitigate some of these problematic AES.

It’s a new approach and we’ll take all the learnings from prior CAR T studies [into consideration]; the team that will be administering the CAR T and overseeing how the patients do during treatment and afterwards are experts. I am a pancreatic cancer surgeon and clinical trials researcher, so I don't personally have experience treating patients with CAR T therapy, but importantly, we have a very robust team. We'll have individuals with expertise in the specific diseases that are being treated and also [clinicians] on the team [with] expertise in CAR T therapy and all the nuances of executing treatment and mitigating any other AEs that may occur.

How can EVEREST-1 potentially affect the treatment paradigm for patients with solid tumors?

I had a conversation with Will Go, MD, PhD, who is the chief medical officer [at A2 Bio], approximately 4 years ago and I [mentioned that finding] more effective therapies for pancreatic cancer is a holy grail. Pancreatic cancer has been particularly recalcitrant to immunotherapy and I asked Will to reach out to me when he thought that there might be something viable in the immunotherapy space that pancreatic cancer patients might be eligible for.

He reached out as this concept got developed, and in looking at the pretty compelling preclinical data and the robustness of the scientific strategy, I thought this really had a chance. Of course, the proof is always in the pudding and we'll have to see what the results are in patients, but we have the opportunity to provide something very unique. Our goal is also to learn from patients on trials and to partner the clinical trial with some very robust translational science so that we can understand the penetrance of the CAR T cells into the tumor and how that affects patient responses.

What are some questions that could still be lingering even after the completion of EVEREST-1?

Is this kind of therapy alone sufficient? Will there need to be any sequencing with this kind of therapy? Does prior chemotherapy have any effect on the effectiveness of this therapy?

We're learning from our single-cell work that prior chemotherapy may in fact be immunosuppressive in function, so we may want to give some thought on how we best deploy this therapy. [In EVEREST-1], it's being deployed in patients who have recurrent metastatic disease, but if there is some signal [of efficacy] here, we could think about its potential application in the adjuvant setting or potentially in the neoadjuvant setting. These are all open questions that need to be addressed. Importantly, we want to be in a position to learn from every patient that's on the trial and to address them effectively.


  1. A study to evaluate the safety and efficacy of A2B530, a Logic-gated CAR T, in subjects with solid tumors that express CEA and have lost HLA-A*02 expression (EVEREST-1). Updated February 21, 2023. Accessed April 10, 2023.
  2. Hecht RJ, Sandberg M, Wang X, et al. A2B530, an autologous CEA-directed Tmod T-cell therapy with an inhibitory receptor gated by HLA-A*02 to target colorectal, pancreatic, and lung cancer.
    J Immunother Cancer. 2022;10:229 doi:10.1136/jitc-2022-SITC2022.0229

Related Videos
Michelle Krogsgaard, PhD
Marc J. Braunstein, MD, PhD
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Joshua K. Sabari, MD
Jeffrey S. Weber, MD, PhD
Nina D'Abreo, MD
Nina D'Abreo, MD
Yelena Novik, MD